Keybank National Association OH Has $551,000 Position in Exact Sciences Corporation (EXAS)

Keybank National Association OH cut its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 36.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,695 shares of the medical research company’s stock after selling 6,598 shares during the quarter. Keybank National Association OH’s holdings in Exact Sciences Corporation were worth $551,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Exact Sciences Corporation by 8.0% in the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after buying an additional 700,051 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Exact Sciences Corporation by 1.2% in the second quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock valued at $243,518,000 after buying an additional 80,589 shares in the last quarter. Fred Alger Management Inc. purchased a new stake in shares of Exact Sciences Corporation in the second quarter valued at approximately $84,177,000. Lord Abbett & CO. LLC boosted its stake in shares of Exact Sciences Corporation by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after buying an additional 875,527 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Exact Sciences Corporation by 32.7% in the second quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after buying an additional 571,796 shares in the last quarter. Hedge funds and other institutional investors own 85.65% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://stocknewstimes.com/2017/11/17/keybank-national-association-oh-has-551000-position-in-exact-sciences-corporation-exas.html.

Exact Sciences Corporation (NASDAQ EXAS) opened at $58.50 on Friday. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last released its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. During the same period in the previous year, the firm posted ($0.36) earnings per share. The business’s revenue for the quarter was up 158.4% compared to the same quarter last year. equities analysts anticipate that Exact Sciences Corporation will post -1.14 EPS for the current fiscal year.

A number of research firms have commented on EXAS. Canaccord Genuity reiterated a “buy” rating and set a $42.00 target price (up from $38.00) on shares of Exact Sciences Corporation in a research report on Thursday, July 20th. Leerink Swann set a $45.00 target price on Exact Sciences Corporation and gave the stock a “buy” rating in a research report on Thursday, August 24th. Vetr upgraded Exact Sciences Corporation from a “sell” rating to a “buy” rating and set a $41.07 target price on the stock in a research report on Wednesday, August 2nd. Bank of America Corporation reiterated a “buy” rating on shares of Exact Sciences Corporation in a research report on Wednesday, July 26th. Finally, Roth Capital boosted their target price on Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Exact Sciences Corporation currently has a consensus rating of “Buy” and an average target price of $49.98.

In related news, CEO Kevin T. Conroy sold 137,805 shares of the company’s stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total value of $8,149,787.70. Following the completion of the transaction, the chief executive officer now directly owns 967,867 shares in the company, valued at $57,239,654.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Graham Peter Lidgard sold 81,025 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $3,821,139.00. Following the completion of the transaction, the insider now owns 366,519 shares of the company’s stock, valued at $17,285,036.04. The disclosure for this sale can be found here. Over the last three months, insiders sold 415,178 shares of company stock valued at $20,785,358. Insiders own 4.00% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply